Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer

被引：0
|
作者：
Hannelore Denys
Corina L. Martinez-Mena
Marc T. Martens
Randal G. D’Hondt
Marie-Pascale L. Graas
Ella Evron
Georgeta Fried
Noa E. Ben-Baruch
Christof Vulsteke
Mona M. Van Steenberghe
机构：
[1] UZ Gent,Integrated Cancer Center Ghent
[2] CHU St Pierre,Center for Oncological Research (CORE)
[3] AZ Turnhout,undefined
[4] AZ Damiaan,undefined
[5] CHC - Clinique Saint-Joseph,undefined
[6] Assaf Harofeh Medical Center,undefined
[7] Rambam Medical Center,undefined
[8] Kaplan Medical Center,undefined
[9] AZ Maria Middelares,undefined
[10] Antwerp University,undefined
[11] Roche nv/sa,undefined
来源：
Breast Cancer Research and Treatment | 2020年 / 181卷
关键词：
Safety; Tolerability; Subcutaneous trastuzumab; HER2-positive early breast cancer; At home administration;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：97 / 105
页数：8
相关论文
共 50 条
  • [41] Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial
    van Ramshorst, Mette S.
    van der Voort, Anna
    van Werkhoven, Erik D.
    Mandjes, Ingrid A.
    Kemper, Inge
    Dezentje, Vincent O.
    Oving, Irma M.
    Honkoop, Aafke H.
    Tick, Lidwine W.
    van de Wouw, Agnes J.
    Mandigers, Caroline M.
    van Warmerdam, Laurence J.
    Wesseling, Jelle
    Peeters, Marie-Jeanne T. Vrancken
    Linn, Sabine C.
    Sonke, Gabe S.
    LANCET ONCOLOGY, 2018, 19 (12) : 1630 - 1640
  • [42] Trastuzumab Emtansine: A Review of Its Adjuvant Use in Residual Invasive HER2-Positive Early Breast Cancer
    Lyseng-Williamson, Katherine A.
    DRUGS, 2020, 80 (16) : 1723 - 1730
  • [43] Trastuzumab plus Capecitabine and Docetaxel as First-line Therapy for HER2-positive Metastatic Breast Cancer: Phase II Results
    Michalaki, Vasiliki
    Fotiou, Stylianos
    Gennatas, Spyridon
    Gennatas, Constantine
    ANTICANCER RESEARCH, 2010, 30 (07) : 3051 - 3054
  • [44] Trastuzumab - A review of its use in the management of HER2-positive metastatic and early-stage breast cancer
    Plosker, GL
    Keam, SJ
    DRUGS, 2006, 66 (04) : 449 - 475
  • [45] The comparative efficacy and risk of harms of the intravenous and subcutaneous formulations of trastuzumab in patients with HER2-positive breast cancer: a rapid review
    Van den Nest, Miriam
    Glechner, Anna
    Gold, Maria
    Gartlehner, Gerald
    SYSTEMATIC REVIEWS, 2019, 8 (01)
  • [46] Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial
    Barcenas, C. H.
    Hurvitz, S. A.
    Di Palma, J. A.
    Bose, R.
    Chien, A. J.
    Iannotti, N.
    Marx, G.
    Brufsky, A.
    Litvak, A.
    Ibrahim, E.
    Alvarez, R. H.
    Ruiz-Borrego, M.
    Chan, N.
    Manalo, Y.
    Kellum, A.
    Trudeau, M.
    Thirlwell, M.
    Saenz, J. Garcia
    Hunt, D.
    Bryce, R.
    McCulloch, L.
    Rugo, H. S.
    Tripathy, D.
    Chan, A.
    ANNALS OF ONCOLOGY, 2020, 31 (09) : 1223 - 1230
  • [47] Outcomes of HER2-positive early-stage breast cancer in the trastuzumab era: a population-based study of Canadian patients
    Zurawska, U.
    Baribeau, D. A.
    Giilck, S.
    Victor, C.
    Gandhi, S.
    Florescu, A.
    Verma, S.
    CURRENT ONCOLOGY, 2013, 20 (06) : E539 - E545
  • [48] Proxalutamide in patients with AR-positive metastatic breast cancer: Results from an open-label multicentre phase Ib study and biomarker analysis
    Jiang, Hanfang
    Ouyang, Quchang
    Yin, Yongmei
    Tong, Zhongshen
    Shen, Kunwei
    Yuan, Zhongyu
    Geng, Cuizhi
    Liu, Yaxin
    Song, Guohong
    Ran, Ran
    Li, Wei
    Qu, Qing
    Wang, Meiyu
    Meng, Luping
    Tong, Youzhi
    Li, Huiping
    EUROPEAN JOURNAL OF CANCER, 2022, 176 : 1 - 12
  • [49] Clinical observation of neoadjuvant chemotherapy with pyrotinib plus trastuzumab in HER2-positive breast cancer: a cohort study
    Li, Qi
    Wang, Yanyan
    Zhu, Mingzhi
    Gu, Yuanting
    Tang, Yajing
    GLAND SURGERY, 2021, 10 (12) : 3389 - 3402
  • [50] Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer
    Tolaney, Sara
    Burris, Howard
    Gartner, Elaina
    Mayer, Ingrid A.
    Saura, Cristina
    Maurer, Matthew
    Ciruelos, Eva
    Garcia, Agustin A.
    Campana, Frank
    Wu, Bin
    Xu, Yi
    Jiang, Jason
    Winer, Eric
    Krop, Ian
    BREAST CANCER RESEARCH AND TREATMENT, 2015, 149 (01) : 151 - 161
12345